Since AFP is an important clinical tumor marker for HCC growth and aggressiveness, we examined the effects of GSK1838705A and OSI-906 on Regorafenib/VK1-mediated inhibition of AFP secretion levels in HCC cell lines. The gene discussed is AFP; the disease is hepatocellular carcinoma.